Verrica Pharmaceuticals (Nasdaq: VRCA) will host a conference call and live webcast at 4:30 p.m. ET on Thursday, August 6, 2026, to discuss second quarter 2026 financial results and provide a corporate update. Participants can join via domestic dial-in 1-800-225-9448, international 1-203-518-9708, using conference ID: VERRICA, or through the investor relations section of the company website.
A replay of the webcast will be archived on Verrica’s website for 90 days. Verrica develops and commercializes treatments for dermatological diseases, including FDA-approved YCANTH (VP-102) for molluscum contagiosum, and is developing YCANTH for common warts and VP-315 under license from Lytix Biopharma for non-melanoma skin cancers.
Loading...
Loading translation...
Positive
None.
Negative
None.
Market Context
The tag-matched record contains a 12.58% gain and a -2.44% decline after prior earnings-date notices...
Analysis
The tag-matched record contains a 12.58% gain and a -2.44% decline after prior earnings-date notices. That split tempers interpretation of this scheduling item; the ineffective S-3 resale registration for stockholder resales is a relevant capital-structure consideration.
Key Figures
Reporting period end:June 30, 2026Conference call date:August 6, 2026Conference call time:4:30 p.m. ET+3 more
6 metrics
Reporting period endJune 30, 2026Second quarter financial results
Conference call dateAugust 6, 2026Second-quarter results and corporate update
Conference call time4:30 p.m. ETAugust 6, 2026
Webcast replay period90 daysFollowing the event
U.S. affected population6 million peopleMolluscum contagiosum
Approved patient age2 years and olderFDA-approved YCANTH treatment
"treatment for adult and pediatric patients two years of age and older with molluscum contagiosum"
Molluscum contagiosum is a common viral skin infection that causes small, painless bumps or lesions on the skin. While it primarily affects children and healthy adults, it can spread easily through skin contact. For investors, understanding health conditions like this highlights the importance of healthcare companies involved in treatments and the potential impact of infectious diseases on public health and economic stability.
cantharidinmedical
"YCANTH® (VP-102) (cantharidin), is the first and only"
A naturally occurring blistering chemical produced by certain beetles, used historically and in medicine as a topical agent to remove warts and lesions and investigated as a raw material for drug development. It matters to investors because companies that manufacture, reformulate, or develop therapies involving cantharidin face regulatory review, manufacturing and safety controls, potential liability, and market opportunity tied to clinical results and approvals; think of it as a powerful, concentrated skin irritant used under medical oversight like a targeted chemical peel.
basal cell carcinomamedical
"non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma"
A type of skin cancer that starts in the cells at the bottom layer of the skin and usually grows slowly and stays local rather than spreading to other organs. It matters to investors because its high frequency and generally surgical treatment drive steady demand for diagnostics, procedures, topical or surgical products, and follow‑on therapies, while new drugs, devices or regulatory approvals can shift market value and reimbursement dynamics. Think of it as a common maintenance issue whose repair options and costs influence healthcare spending and related businesses.
squamous cell carcinomamedical
"including basal cell carcinoma and squamous cell carcinoma"
Squamous cell carcinoma is a type of skin cancer that develops when the cells in the outer layer of the skin grow abnormally and uncontrollably. It can also occur in other parts of the body, such as the mouth or throat. For investors, understanding diseases like this is important because they can impact healthcare companies, influence medical research funding, and affect overall public health trends.
WEST CHESTER, Pa., July 30, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Thursday, August 6, 2026, to discuss the Company's financial results for the second quarter ending June 30, 2026, and provide a corporate update.
Individuals may participate in the live call via telephone by dialing 1-800-225-9448 (domestic) or 1-203-518-9708 (international) and using the conference ID: VERRICA. Participants are asked to dial in 10 minutes before the start of the call to register.
A live audio webcast of the call can also be accessed by visiting the investor relations section of the Company’s website, www.verrica.com, or by clicking here. A replay of the webcast will be archived on Verrica’s website for 90 days following the event.
About Verrica Pharmaceuticals Inc. Verrica is a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers. Verrica’s product YCANTH® (VP-102) (cantharidin), is the first and only healthcare professional-administered treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH® (VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (ruxotemitide, formerly known as LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit www.verrica.com.
When will Verrica Pharmaceuticals (VRCA) report its Q2 2026 financial results?
Verrica Pharmaceuticals will discuss its Q2 2026 financial results on a conference call at 4:30 p.m. ET on August 6, 2026. According to Verrica, the call will also include a broader corporate update for investors and analysts.
How can investors join Verrica Pharmaceuticals' Q2 2026 earnings call for VRCA?
Investors can join Verrica’s Q2 2026 call by dialing 1-800-225-9448 (domestic) or 1-203-518-9708 (international) with conference ID VERRICA. According to Verrica, participants should dial in 10 minutes early to register before the call starts.
Will Verrica Pharmaceuticals (VRCA) provide a webcast and replay for the August 6, 2026 call?
Yes, Verrica will provide a live audio webcast via the investor relations section of www.verrica.com. According to Verrica, a replay of the webcast will be archived on the company’s website for 90 days following the August 6, 2026 event.
What does Verrica Pharmaceuticals (VRCA) do in dermatology?
Verrica Pharmaceuticals develops and commercializes medications for dermatological diseases, including certain skin cancers. According to Verrica, its portfolio includes the FDA-approved treatment YCANTH (VP-102) for molluscum contagiosum and pipeline programs targeting common warts and non-melanoma skin cancers such as basal cell and squamous cell carcinoma.
What is YCANTH (VP-102) from Verrica Pharmaceuticals (VRCA)?
YCANTH (VP-102) is a cantharidin-based treatment administered by healthcare professionals for molluscum contagiosum. According to Verrica, it is the first and only FDA-approved treatment for adult and pediatric patients aged two years and older with this highly contagious viral skin infection.
What is VP-315 and Verrica Pharmaceuticals' agreement with Lytix Biopharma for VRCA?
VP-315 (ruxotemitide) is being developed for non-melanoma skin cancers, including basal and squamous cell carcinoma. According to Verrica, it holds a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 in these dermatologic oncology indications.
